Genitourinary Cancers de Siamak Daneshmand

Genitourinary Cancers: Cancer Treatment and Research, cartea 175

Editat de Siamak Daneshmand, Kevin G. Chan

en Limba Engleză Hardback – 14 sep 2018

Observăm în Genitourinary Cancers o abordare clinică riguroasă care debutează prin prioritizarea algoritmilor de decizie în patologii complexe. Un exemplu elocvent inclus în manual este algoritmul pentru tratamentul cancerului de vezică urinară de grad înalt, non-invaziv muscular, care evaluează critic momentele în care chirurgia radicală trebuie devansată pentru a optimiza prognosticul pacientului. Această primă ediție, publicată în seria Cancer Treatment and Research, reușește să ancoreze progresele rapide din imagistică și markerii moleculari direct în practica oncologică cotidiană. Structura volumului este organizată pe grupuri de patologii — prostată, rinichi, vezică și testicul — evoluând de la tehnici noi de imagistică și terapii ablative țintite către managementul bolilor metastatice. Apreciem în mod deosebit secțiunile dedicate imunoterapiei, unde este examinat rolul inhibitorilor punctelor de control, oferind o perspectivă clară asupra modului în care aceste terapii modifică standardele de îngrijire. Editorul Siamak Daneshmand continuă aici expertiza demonstrată în lucrări precum Modern Management of Testicular Cancer sau Urinary Diversion, extinzând analiza de la tehnica chirurgicală pură către protocoalele de recuperare postoperatorie (ERAS) și coordonarea multidisciplinară. Clinicienii care folosesc Urologic Oncology de Kelly L. Stratton ca referință vor găsi în acest volum o completare esențială privind integrarea datelor genomice (precum Cancer Genome Atlas) și a celulelor tumorale circulante (CTC) în stabilirea prognosticului. Față de abordările generale, Genitourinary Cancers se distinge prin focalizarea pe medicina de precizie și pe optimizarea fluxului de îngrijire a pacientului chirurgical, fiind un instrument indispensabil în oncologia urologică modernă.

Citește tot Restrânge

Din seria Cancer Treatment and Research

Preț: 699^.47 lei

Preț vechi: 736^.29 lei
-5%

Puncte Express: 1049

Paperback 814^.98 lei

Hardback 699^.47 lei

Carte tipărită la comandă

Livrare economică 25 mai-08 iunie

Adaugă în coș

Wish list
Gift list
Am citit!

Adaugă în listă

Specificații

ISBN-13: 9783319933382
ISBN-10: 3319933388
Pagini: 316
Ilustrații: VI, 308 p. 39 illus., 38 illus. in color.
Dimensiuni: 160 x 241 x 23 mm
Greutate: 0.64 kg
Ediția:1st ed. 2018
Editura: Springer
Colecția Cancer Treatment and Research
Seria Cancer Treatment and Research

Locul publicării:Cham, Switzerland

De ce să citești această carte

Recomandăm această lucrare urologilor și oncologilor care doresc să integreze rapid protocoalele de imunoterapie și noii markeri moleculari în practica lor. Cititorul câștigă acces la algoritmi decizionali clari pentru cazurile dificile de cancer de vezică și testicul, beneficiind de expertiza editorilor în optimizarea recuperării postoperatorii. Este o resursă esențială pentru tranziția de la chirurgia clasică la managementul multidisciplinar bazat pe dovezi genetice și imunologice.

Despre autor

Siamak Daneshmand este un expert recunoscut în oncologie urologică, cu un interes particular pentru cancerul de vezică și cel testicular. În calitate de editor, el a coordonat volume de referință precum Modern Management of Testicular Cancer, publicat sub egida Urologic Clinics, unde a pus accent pe modalitățile de diagnostic și tehnicile chirurgicale avansate. Lucrările sale, inclusiv Urinary Diversion, reflectă o preocupare constantă pentru reconstrucția chirurgicală și managementul complicațiilor, consolidându-i reputația de lider în dezvoltarea protocoalelor clinice pentru malignitățile genitourinare complexe.

Descriere scurtă

This book addresses the most pressing current questions in the management of urologic malignancies. The rapid advances in imaging and molecular markers are placed into a clinical context, with explanation of their effects on prognosis and treatment planning. Similarly, progress in immunotherapy is carefully examined, focusing in particular on the role of immune checkpoint inhibitors in both early- and late-stage urologic malignancies. Looking beyond the improvements in minimally invasive techniques for urologic cancers, the impacts of care coordination pathways and enhanced recovery after surgery protocols are reviewed. Readers will also find enlightening discussion of the decision algorithm for the treatment of early-stage, high-grade bladder cancer, taking into account evidence on the most advanced treatment options and the circumstances in which surgery may need to be expedited. The penultimate chapter discusses the Cancer Genome Atlas project for bladder cancer, and the book closes by considering contemporary medical and surgical management of testicular cancer.

Cuprins

New Imaging Techniques in Prostate Cancer.- Targeted ablative therapies for prostate cancer.- Prostate cancer markers.- Prognostic value of CTC’s in urologic cancers.- Management of Small Renal Masses.- Advances in the Treatment of Metastatic Renal Cell Carcinoma.-Imaging in urologic cancers .- Molecular prognostication in Bladder cancer.- Early cystectomy for high risk non-muscle invasive disease.- Care-coordination pathway after radical cystectomy.- Current role of checkpoint inhibitors in urologic cancers.- ) The Cancer Genome Atlas Project.- Prognostic models in germ cell tumors.- Modern management of testicular cancer.

Notă biografică

Dr. Sia Daneshmand earned his medical degree at the University of California, Davis and completed his residency at the University of Southern California (USC) followed by a two-year fellowship in Urologic Oncology at the USC/Norris Comprehensive Cancer Center. He spent almost 6 years at Oregon Health and Science University and was then recruited to USC Institute of Urology in 2010 as Director of Urologic Oncology. He is currently an Associate Professor of Urology with Clinical Scholar designation and serves as director of clinical research as well as the urologic oncology (SUO) fellowship director. Dr. Daneshmand’s main interests include bladder cancer, advanced kidney cancer and testicular cancer. He has extensive experience in urinary diversion and reconstruction following radical cystectomy as well as nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testis cancer. He is one of the highest volume surgeons for these diseases inthe country. He also has extensive experience in the management of advanced kidney cancers with vena caval tumor thrombus involvement, as well as prostate cancer, retroperitoneal sarcomas and surgeries requiring replacement of the great vessels. His main research interests focus on the use of pathways to improve peri-operative outcomes following radical cystectomy, use of serum and molecular markers and new technologies in diagnosis and management of bladder cancer, as well as functional outcomes following orthotopic urinary diversion. He is a leading authority on enhanced recovery after surgery (ERAS) following radical cystectomy and his protocol has significantly reduced hospital stay while improving the patient experience. He serves on the editorial board of the Journal of Urology, Bladder Cancer Journal, Current Opinions in Urology, the scientific advisory board of Bladder Cancer Advocacy Network (BCAN) as well as the AUA/SUO Guideline Committee on non-muscle invasive bladdercancer as well as testicular cancer. He is a member of Alpha Omega Alpha medical honor society and has been designated one of the “America’s Top Cancer Doctors” for the past 8 consecutive years. He is an active member of the Society of Urologic Oncology, has presented over 300 abstracts at scientific meetings and has authored over 200 peer-reviewed articles, reviews, and book chapters.

Dr. Kevin Chan earned his medical degree at the University of Southern California and completed his urology training at the University of Southern California. Following his training, he joined the urology faculty at City of Hope Cancer Center in Duarte, California. He is currently a Clinical Associate Professor of Surgery in the Division of Urology and the Head of Reconstructive Urology at City of Hope Cancer Center.
At City of Hope, Dr. Chan has established one of the largest programs in continent urinary diversion using robot-assisted laparoscopic radical cystectomy for the treatment of bladder cancer. In addition to his clinical practice, Dr. Chan conducts research in surgical techniques and postoperative pathways that will help minimize complications and improve outcomes in the treatment of bladder cancer. He has vast experience in the surgical treatment of male urinary incontinence and has created a database at City of Hope with the goal of improving surgical techniques used to treat male urinary incontinence. Dr. Chan's research interests also include the development of novel diagnostic techniques to improve the detection and progression of prostate cancer.

Caracteristici

Provides insights into questions of key importance for the current management of renal, prostate, bladder, and testicular cancers Covers the full range of management issues with regard to diagnosis, therapy, prognosis, and postoperative care Takes into account the latest available evidence on all topics